| Jan 8, 2026 | Parabilis Medicines | $305.0M Series F | Jake Simson | Catalio Capital Management, Foresite Capital, ARCH Venture Partners, Farallon Capital Management, Frazier Life Sciences, Freepoint Capital Group, General Catalyst, HBM Healthcare Investments, Invus, Marshall Wace, Milky Way Investments, Nextech Invest, Rock Springs Capital, Sixty Degree Capital, Soleus Capital, T. Rowe Price Associates |
| Dec 16, 2025 | BlossomHill Therapeutics | $84.0M Series B Extension | Brahma Capital, Vish Sridharan | OrbiMed, Plaisance Capital Management, Vivo Capital |
| Nov 20, 2025 | Aspen Neuroscience | $115.0M Series C | ARCH Venture Partners, Frazier Life Sciences, OrbiMed, Revelation Partners | Axon Ventures, Balyasny Asset Management, Cindy Perettie, LifeForce Capital, LYFE Capital, Medical Excellence Capital, Prebys Ventures Fund, Section 32 |
| Sep 23, 2025 | Ensoma | $53.0M Other Equity | — | 5AM Ventures, Bill & Melinda Gates Foundation, Catalio Capital Management, Delos Capital, F-Prime Capital, Gilead Sciences, Hanwha Impact, Mirae Asset, Qatar Investment Authority, RTW Investments, Solasta Ventures, SymBiosis, Viking Global Investors |
| May 1, 2025 | Fore Biotherapeutics | $40.0M Series D | — | Roberto De Ponti, 3B Future Health Ventures (Helsinn Investment Fund), Hbm Partners, Novartis Venture Fund, Pontifax Venture Capital, SR One, 3B Future Health Fund, Medicxi, Novartis, OrbiMed, Wellington Management |
| May 1, 2025 | Antares Therapeutics | $180.0M Series A | Atlas Venture, Shelley Chu, Otello Stampacchia, BVF Partners, Cormorant Asset Management | Frazier Healthcare Partners, Polaris Partners, Vida Ventures, Invus, Tenmile, Vinyanshu Ventures, Willett Advisors, Abingworth |
| Oct 1, 2024 | Axonis Therapeutics | $120.0M Series A | Cormorant Asset Management | America's Frontier Fund, BoxOne Ventures, Sierra Ventures, Sofinnova Investments |
| Sep 1, 2024 | GC Therapeutics | $65.0M Series A | Raymond Kelleher | ARCH Venture Partners, F-Prime Capital Partners, FTX Ventures, General Catalyst, Lux Capital, Mubadala, Y Combinator, Arash Ferdowsi, Balaji Srinivasan, Eoghan McCabe, Karim Atiyeh, Scott Belsky |
| Jul 10, 2024 | Adona Medical | $33.5M Series C | Cormorant Asset Management | — |
| Jul 1, 2024 | Third Arc Bio | $170.0M Series A | Vida Ventures, Cormorant Asset Management, Hillhouse Capital Group | Sofinnova Investments, AbbVie Ventures, abrdn, BVF Partners, Foresite Capital, Freepoint Capital Group, Goldman Sachs, Janus Henderson Investors, Logos Capital, Marshall Wace, Francesco Draetta, Loretta Tse, T. Rowe Price Associates |
| May 9, 2024 | Aardvark | $85.0M Series C | Victor Tong | Cantor Fitzgerald, Theresa Strong, Laurion Capital Management, LG Technology Ventures, Silver Arc Private Capital, Surveyor Capital, SymBiosis, Tetragon Financial Group, Stacy Ward, Vickers Venture Partners, Walleye Capital |
| May 7, 2024 | Averto Medical | $30.0M Series A | Bihua Chen | CVF, LifeSci Venture Partners, Venrock |
| May 1, 2024 | AltruBio | $230.0M Series B | Gorjan Hrustanovic | RA Capital, Third Rock Ventures, Alice Zhang, Evan Cheng, Blackstone, Jake Simson, Soleus Capital |
| Mar 1, 2024 | Alumis | $260.0M Series C | Foresite Capital, Srinivas Akkaraju | ARCH Venture Partners, Atlas Venture, Deerfield Management, F-Prime Capital Partners, The Column Group, venBio, Ally Bridge Group, AyurMaya, HBM Healthcare Investments, Lilly Asia Ventures, Nextech, Omega Funds, Piper Heartland Healthcare Capital, SR One |
| Feb 9, 2024 | Neurona Therapeutics | $120.0M Other Equity | Cormorant Asset Management | — |
| Feb 1, 2024 | BioAge Labs | $170.0M Series D | Sofinnova Investments | F-Prime Capital Partners, Highbury Group, Johnson & Johnson Innovation, Third Rock Ventures, Uprising, VZVC, Amgen Ventures, Bio + Health, Lilly Ventures, Patrick Enright, OrbiMed, Osage University Partners, Pivotal bioVenture Partners, RA Capital Management, RTW Investments, Sands Capital, SV Health Investors |
| Feb 1, 2024 | FogPharma | $150.0M Series E | Thilo Schroeder | Lux Capital, Nextech Invest, The Column Group, venBio, Alex Gorsky, ARCH Venture Partners, Catalio Capital Management, Farallon Capital Management, Fidelity Management & Research Company, Foresite Capital, General Catalyst, Google Ventures, Invus, Marshall Wace, Milky Way Investments, RA Capital Management, Rock Springs Capital, Samsara BioCapital, Sixty Degree Capital, SymBiosis, T. Rowe Price Associates |
| Jan 1, 2024 | BlossomHill Therapeutics | $100.0M Series B | Sundeep Agrawal | General Catalyst, OrbiMed, Sofinnova Investments, Bihua Chen, H&D Asset Management, Hercules BioVentures Partners, Plaisance Capital Management, Timothy Stubbs |
| Dec 1, 2023 | Synnovation Therapeutics | $100.0M Series A | Third Rock Ventures | Johnson & Johnson Innovation, Sofinnova Investments, Judith Li, Thilo Schroeder, Ting Feng |
| Nov 21, 2023 | Supira Medical | $40.0M Series D | Cormorant Asset Management | — |
| Oct 3, 2023 | Akura Medical | $35.0M Series B | Cormorant Asset Management, Gautam Kainth | AMED Ventures, Lilly Asia Ventures, PA MedTech, Unorthodox Ventures |
| Oct 1, 2023 | Triveni Bio | $92.0M Series A | Atlas Venture, Cormorant Asset Management | Polaris Partners |
| Sep 1, 2023 | Star Therapeutics | $90.0M Series C | Sofinnova Investments | Foresite Capital, OrbiMed, Sanofi Ventures, Versant Ventures, Westlake Village BioPartners, Agent Capital, Catalio Capital Management, Cowen Healthcare Investments, Vijay Lathi, NYBC Ventures, Qatar Investment Authority, Matthew Hammond, Amrit Nagpal, Soleus Capital |
| Aug 1, 2023 | Rapport Therapeutics | $150.0M Series B | Raymond Kelleher | General Catalyst, Johnson & Johnson Innovation, OrbiMed, Sofinnova Investments, Third Rock Ventures, Sanjay Mistry, ARCH Venture Partners, Fidelity Management & Research Company, Goldman Sachs, Johnson & Johnson Innovation, Logos Capital, Perceptive Advisors, Surveyor Capital, T. Rowe Price Associates |
| Aug 1, 2023 | ADARx Pharmaceuticals | $200.0M Series C | Ricky Sun, Chen Yu | Andreessen Horowitz, Frazier Healthcare Partners, Ed Mathers, OrbiMed, SR One, Third Rock Ventures, Ascenta Capital, BlackRock, Commodore Capital, HBM Healthcare Investments, Invus, Lilly Asia Ventures, Redmile Group, T. Rowe Price Associates, Venrock, Vivo Capital |
